Please ensure Javascript is enabled for purposes of website accessibility

Why GlycoMimetics Is Tumbling 13.4% Today

By Todd Campbell – Jun 5, 2017 at 12:47PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

New data from a trial evaluating one of its most promising drug candidates failed to impress investors.

What happened

After updating industry watchers on the progress for a key cancer drug in development, shares of GlycoMimetics (GLYC -14.45%) are falling 13.4% as of 12:30 p.m. EDT today.

So what

At the American Society of Clinical Oncology (ASCO) annual meeting this week, GlycoMimetics is updating stakeholders on phase 1/2 results for GMI-1271, a drug for use alongside chemotherapy in the treatment of relapsed or refractory acute myeloid leukemia (AML). 

A person prepares to address an audience in front of a microphone.

IMAGE SOURCE: GETTY IMAGES.

The company reports that the overall response rate in 54 evaluable AML patients was 41%, and median overall survival from the phase 1 portion of the study was 7.6 months. In 25 newly diagnosed AML patients over age 60, the overall response rate was 68%. According to management, the data is better than historical controls.

However, the data appears to be a bit weaker than what some might have been looking for. Previously, management said the overall response rate in 42 evaluable patients was 50%, so the declining ORR as more patients become evaluable could be weighing down optimism. 

Today's news comes after shares marched significantly higher last month after management announced that GMI-1271 had received FDA breakthrough designation, which expedites the development and review of drugs. 

GLYC Chart

GLYC data by YCharts.

Now what

Given the share-price run-up, it's not too surprising that shares are giving back some gains today. The data suggest that GlycoMimetics may be onto something with GM-1271, but investors will need to see more mature data from this trial, and possibly from a confirmatory trial, before knowing for sure what the commercial opportunity for it could be. Overall, it's common for clinical trials to fail, even in the later stages of development, so investors are right to approach this data with a healthy dose of skepticism. 

Todd Campbell has no position in any stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.